Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain
- PMID:23994452
- DOI: 10.1016/j.neuroimage.2013.08.035
Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain
Abstract
Only recently the first successful serotonin 2A (5-HT2A) receptor agonist PET radioligands have been described, with [(11)C]Cimbi-36 reported as the most promising in the pig brain so far. Agonist radioligands may target specifically the G protein-coupled state of the receptors and thereby provide a more meaningful assessment of available receptors than antagonist radioligands. In the current study we characterized [(11)C]Cimbi-36 receptor binding in the primate brain. On five experimental days, a total of 14 PET measurements were conducted in three female rhesus monkeys. On each day, PET measurements were conducted after intravenous injection of [(11)C]Cimbi-36 during baseline conditions and after intravenous infusion of the 5-HT2 receptor antagonist ketanserin (n=3) or the 5-HT2C receptor antagonist SB 242084 (n=2). On four of the experimental days an additional baseline PET measurement was conducted after injection of [(11)C]MDL 100907. All PET measurements were performed for 2h in a HRRT PET system and arterial blood was obtained for measurement of the [(11)C]Cimbi-36 input function. Quantification of [(11)C]Cimbi-36 receptor binding was performed using kinetic and graphical analysis. After injection of [(11)C]Cimbi-36 the regional distribution of radioactivity in brain was in accordance with the known 5-HT2 receptor distribution. The two-tissue compartment model was superior for the description of the time-radioactivity curves of all examined brain regions. BPND values obtained with reference tissue models correlated with corresponding values obtained with kinetic modeling. Administration of ketanserin decreased the binding in all brain regions but did not affect the cerebellar distribution volume. The BPND of [(11)C]Cimbi-36 was 56±8% of [(11)C]MDL 100907 across cortical regions, but higher in other brain regions including choroid plexus. After administration of SB 242084, [(11)C]Cimbi-36 binding was nearly completely inhibited in the choroid plexus, partly reduced in several subcortical regions (e.g. hippocampus), but not affected in the cortical regions. In conclusion, the receptor binding of [(11)C]Cimbi-36 can be quantified using kinetic modeling and the cerebellum was found to be a suitable reference region. The difference between [(11)C]Cimbi-36 and [(11)C]MDL 100907 binding in the choroid plexus is related to 5-HT2C receptor binding of [(11)C]Cimbi-36. [(11)C]Cimbi-36 is the first agonist radioligand suitable for examination of 5-HT2A receptors in the cortical regions and of 5-HT2C receptors in the choroid plexus of the primate brain.
Keywords: 5-HT(2A); 5-HT(2C); Agonist; Monkey; Serotonin receptors; [(11)C]Cimbi-36.
© 2013.
Similar articles
- Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin.Ettrup A, Svarer C, McMahon B, da Cunha-Bang S, Lehel S, Møller K, Dyssegaard A, Ganz M, Beliveau V, Jørgensen LM, Gillings N, Knudsen GM.Ettrup A, et al.Neuroimage. 2016 Apr 15;130:167-174. doi: 10.1016/j.neuroimage.2016.02.001. Epub 2016 Feb 11.Neuroimage. 2016.PMID:26876490
- Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, Jørgensen LM, Hansen M, Baandrup AO, Bache S, Svarer C, Kristensen JL, Gillings N, Madsen J, Knudsen GM.Ettrup A, et al.J Cereb Blood Flow Metab. 2014 Jul;34(7):1188-96. doi: 10.1038/jcbfm.2014.68. Epub 2014 Apr 30.J Cereb Blood Flow Metab. 2014.PMID:24780897Free PMC article.Clinical Trial.
- Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.Yang KC, Stepanov V, Martinsson S, Ettrup A, Takano A, Knudsen GM, Halldin C, Farde L, Finnema SJ.Yang KC, et al.Int J Neuropsychopharmacol. 2017 Sep 1;20(9):683-691. doi: 10.1093/ijnp/pyx051.Int J Neuropsychopharmacol. 2017.PMID:28911007Free PMC article.
- Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging.T L'Estrade E, Hansen HD, Erlandsson M, Ohlsson TG, Knudsen GM, Herth MM.T L'Estrade E, et al.ACS Chem Neurosci. 2018 Jun 20;9(6):1226-1229. doi: 10.1021/acschemneuro.8b00176. Epub 2018 May 15.ACS Chem Neurosci. 2018.PMID:29763291Review.
- A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.Palacios JM, Pazos A, Hoyer D.Palacios JM, et al.Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418. doi: 10.1007/s00213-017-4545-5. Epub 2017 Mar 7.Psychopharmacology (Berl). 2017.PMID:28265714Review.
Cited by
- (18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study.Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang T, Neumeyer JL, George SR, Seeman P, Stabin MG, Jonsson C, Farde L, Halldin C.Finnema SJ, et al.J Nucl Med. 2014 Jul;55(7):1164-70. doi: 10.2967/jnumed.113.133876. Epub 2014 May 1.J Nucl Med. 2014.PMID:24790219Free PMC article.
- Synthesis and Evaluation of [11C]7-Halogen-2-Phenyl Isoindolone Derivatives: Potential PET Radioligands forin vivo Imaging of 5-HT2C Receptors.Zeng F, Nye JA, Voll RJ, Mun J, Goodman MM.Zeng F, et al.Front Neurosci. 2021 Nov 26;15:766320. doi: 10.3389/fnins.2021.766320. eCollection 2021.Front Neurosci. 2021.PMID:34899169Free PMC article.
- Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.Jucaite A, Stenkrona P, Cselényi Z, De Vita S, Buil-Bruna N, Varnäs K, Savage A, Varrone A, Johnström P, Schou M, Davison C, Sykes A, Pilla Reddy V, Hoch M, Vazquez-Romero A, Moein MM, Halldin C, Merchant MS, Pass M, Farde L.Jucaite A, et al.Neuro Oncol. 2021 Apr 12;23(4):687-696. doi: 10.1093/neuonc/noaa238.Neuro Oncol. 2021.PMID:33123736Free PMC article.Clinical Trial.
- A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain.Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, Knudsen GM.Raval NR, et al.Int J Mol Sci. 2021 Jan 15;22(2):835. doi: 10.3390/ijms22020835.Int J Mol Sci. 2021.PMID:33467676Free PMC article.
- Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans.da Cunha-Bang S, Ettrup A, Mc Mahon B, Skibsted AP, Schain M, Lehel S, Dyssegaard A, Jørgensen LM, Møller K, Gillings N, Svarer C, Knudsen GM.da Cunha-Bang S, et al.Transl Psychiatry. 2019 Apr 11;9(1):134. doi: 10.1038/s41398-019-0468-8.Transl Psychiatry. 2019.PMID:30975977Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources